PTT-4256
Pathios Therapeutics
['thio']
 2023 update: pathios unveils ptt-4256, an internally discovered, oral, highly potent, and selective small molecule inhibitor of gpr65. compound shows excellent drug-like properties and impressive anti-tumor activity in preclinical #cancer models. 
We’re an early-stage VC firm that invests in entrepreneurs with visionary ideas who want to make a difference in technology and healthcare.